Physician profile
Danielle Weiss
NPI 1528454402
$5,420.97
in general payments reported to CMS, 2019-2025
48 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $87.79 · 2021: $327 · 2022: $1,238 · 2023: $1,481 · 2024: $1,240 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,647.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $727.81 | 2022-2025 | Xcopri |
| Ucb, INC. | $720.43 | 2020-2025 | Briviact, Rystiggo, Nayzilam |
| Neurelis, INC. | $535.06 | 2021-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $400.95 | 2023-2025 | Fycompa |
| Jazz Pharmaceuticals INC. | $399.37 | 2022-2025 | |
| Livanova USA, INC. | $363.27 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $177.10 | 2019-2024 | Ultomiris, Soliris |
| Argenx US, INC. | $146.95 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $137.71 | 2020-2023 | |
| Tanabe Pharma America, INC. | $127.33 | 2023-2025 | Radicava |
| Amgen INC. | $106.77 | 2022 | |
| Ns Pharma, INC. | $102.94 | 2021-2024 | Viltepso |
| Alnylam Pharmaceuticals INC. | $99.10 | 2024-2025 | Amvuttra |
| Acadia Pharmaceuticals INC | $91.15 | 2023-2025 | Daybue |
| Harmony Biosciences LLC | $84.82 | 2023-2025 | Wakix |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.